Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

IV Treatment May Lower Risk of Dying From Bacterial Meningitis

30.09.2010
New research shows that an intravenous (IV) treatment may cut a person’s risk of dying from bacterial meningitis. The research is published in the September 29, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology. The treatment is called dexamethasone.

“Using this treatment in people infected with meningitis has been under debate because in a few large studies it was shown to be ineffective,” said study author Diederik van de Beek, MD, PhD, with the Academic Medical Center, University of Amsterdam in the Netherlands and a member of the American Academy of Neurology. “Our results provide valuable evidence suggesting that dexamethasone is effective in adult cases of bacterial meningitis and should continue to be used.”

Bacterial meningitis is a condition that causes membranes in the brain and spinal cord to become inflamed. The disease can be deadly, or result in hearing loss, brain damage and learning disabilities. Pneumococcal meningitis is the most common and severe form of bacterial meningitis. It is estimated that about 25 to 30 percent of people die from the disease.

For the study, researchers evaluated 357 Dutch people age 16 or older with pneumococcal meningitis between 2006 and 2009. Of those, 84 percent were given dexamethasone through an IV with or before the first dose of antibiotics. The results were compared to an earlier study of 352 people treated for bacterial meningitis in 1998-2002, before Netherlands guidelines recommended using dexamethasone. In that study, only three percent of the people were given dexamethasone.

In both studies, participants were assessed on a rating scale of one to five. A score of one was given for death, two for coma, three for severe disability, four for moderate disability and five for mild or no disability. In the later study, 39 percent had an “unfavorable outcome,” or a score of four or lower on the scale, compared to 50 percent in the earlier study group.

The study found that the rate of death for those who were given dexamethasone was 10 percent lower than in those in early study group. The rates of hearing loss were also nearly 10 percent lower for those in the later study group.

Symptoms of bacterial meningitis are neck stiffness, fever and an altered mental state. These are also symptoms of viral meningitis, which is more common, much less serious and was not the focus of this study. Bacterial meningitis is a medical emergency and is diagnosed by culturing bacteria from the spinal fluid or by observing changes in the spinal fluid which indicate the presence of bacteria. Bacterial meningitis must always be treated with antibiotics in addition to medications like dexamethasone, which is a medication of the glucocorticosteroid class of drugs and may be used for bacterial meningitis.

The study was supported by the Netherlands Organization for Health Research and Development and the Academic Medical Center, University of Amsterdam.

The American Academy of Neurology, an association of more than 22,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as multiple sclerosis, restless legs syndrome, Alzheimer’s disease, narcolepsy, and stroke.

For more information about the American Academy of Neurology, visit http://www.aan.com.

VIDEO: http://www.youtube.com/AANChannel
TEXT: http://www.aan.com/press
TWEETS: http://www.twitter.com/AANPublic

Rachel L. Seroka | American Academy of Neurology
Further information:
http://www.aan.com

More articles from Studies and Analyses:

nachricht The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung

nachricht A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>